Abstract
A series of 19 isonicotinic acid hydrazide derivatives has been synthesized and evaluated for their in vitro antitubercular activity against Mycobacterium tuberculosis H37Rv using alamar blue susceptibility test. The synthesized compounds inhibit Mycobacterium tuberculosis H37Rv strain with minimum inhibitory concentration ranging from (0.00014-0.01174 mM). Among all synthesized compounds seven derivatives 2a, 2b, 2e, 2h, 2l, 2m and 2q were more potent than isoniazid and the compound 2q emerged as the most potent derivative, being more effective than isoniazid with an (MIC 0.00023 mM) in vitro. The results demonstrated the potential and importance of developing new isoniazid derivatives against Mycobacterium infections.
Keywords: Isonicotinoyl hydrazones, Mycobacterium tuberculosis H37Rv, Antitubercular activity, IR, 1H NMR, C-NMR, hydrazide Derivatives, Antitubercular Agents, Tuberculosis, Mycobacterium tuberculi, amikacin, capreomycin, HIV-1 seropositive, chemotherapy, chromosomal mutation, isonicotinoyl hydrazone
Letters in Drug Design & Discovery
Title: Synthesis, Characterization of (E)-N'-(substituted-benzylidene)isonicotinohydrazide Derivatives as Potent Antitubercular Agents
Volume: 8 Issue: 6
Author(s): Manav Malhotra, Rajiv Sharma, Vikramdeep Monga, Aakash Deep, Kapendra Sahu and Abdul Samad
Affiliation:
Keywords: Isonicotinoyl hydrazones, Mycobacterium tuberculosis H37Rv, Antitubercular activity, IR, 1H NMR, C-NMR, hydrazide Derivatives, Antitubercular Agents, Tuberculosis, Mycobacterium tuberculi, amikacin, capreomycin, HIV-1 seropositive, chemotherapy, chromosomal mutation, isonicotinoyl hydrazone
Abstract: A series of 19 isonicotinic acid hydrazide derivatives has been synthesized and evaluated for their in vitro antitubercular activity against Mycobacterium tuberculosis H37Rv using alamar blue susceptibility test. The synthesized compounds inhibit Mycobacterium tuberculosis H37Rv strain with minimum inhibitory concentration ranging from (0.00014-0.01174 mM). Among all synthesized compounds seven derivatives 2a, 2b, 2e, 2h, 2l, 2m and 2q were more potent than isoniazid and the compound 2q emerged as the most potent derivative, being more effective than isoniazid with an (MIC 0.00023 mM) in vitro. The results demonstrated the potential and importance of developing new isoniazid derivatives against Mycobacterium infections.
Export Options
About this article
Cite this article as:
Malhotra Manav, Sharma Rajiv, Monga Vikramdeep, Deep Aakash, Sahu Kapendra and Samad Abdul, Synthesis, Characterization of (E)-N'-(substituted-benzylidene)isonicotinohydrazide Derivatives as Potent Antitubercular Agents, Letters in Drug Design & Discovery 2011; 8 (6) . https://dx.doi.org/10.2174/157018011795906866
DOI https://dx.doi.org/10.2174/157018011795906866 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Contribution of Antimicrobial Peptides to the Development of New and Efficient Antimicrobial Strategies
Current Proteomics Demographic, Clinical and Laboratory Profiles of HIV Infected Patients Admitted into Imam Khomeini Hospital of Tehran, Iran
Infectious Disorders - Drug Targets Cardiovascular and Pulmonary Manifestations of Systemic Lupus Erythematosus
Current Rheumatology Reviews Editorial [Hot Topic: Tuberculosis (Part 1) (Guest Editor: Douglas B. Lowrie)]
Current Molecular Medicine Graphical Abstracts
Letters in Drug Design & Discovery The Bacterial lux Reporter System: Applications in Bacterial Localisation Studies
Current Gene Therapy Chemokines and Defensins as HIV Suppressive Factors: An Evolving Story
Current Pharmaceutical Design Selection of Microbial T-Cell Epitopes for Immune-Diagnosis, Immune- Therapy and Vaccine Design
Current Pharmacogenomics Investigation of Antituberculosis from Medicinal Plant of Community Ethnic in South Sulawesi
Infectious Disorders - Drug Targets Using Genomics for Natural Product Structure Elucidation
Current Topics in Medicinal Chemistry Prevalence of Tuberculosis in a Prison in Tehran by Active Case Finding
Infectious Disorders - Drug Targets Proteomic analysis of a <i>hom</i>-disrupted, cephamycin C overproducing <i>Streptomyces clavuligerus</i>
Protein & Peptide Letters An Updated Review of ISCOMSTM and ISCOMATRIXTM Vaccines
Current Pharmaceutical Design Thiazolidinedione: A Privileged Scaffold for the Development of Anticancer Agents
Current Topics in Medicinal Chemistry Microemulsions and Nanoemulsions for Targeted Drug Delivery to the Brain
Current Nanoscience Transcription Factors in Autoimmune Diseases
Current Pharmaceutical Design Active Metabolites Resulting from Decarboxylation, Reduction and Ester Hydrolysis of Parent Drugs
Current Drug Metabolism Listeria-Based Anti-Infective Vaccine Strategies
Recent Patents on Anti-Infective Drug Discovery Honey as a Source of Dietary Antioxidants: Structures, Bioavailability and Evidence of Protective Effects Against Human Chronic Diseases
Current Medicinal Chemistry Editorial [Hot Topic: Carbonic Anhydrases: Again, and Again, and Again (Executive Editor: Claudiu T. Supuran)]
Current Pharmaceutical Design